Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Migraine : emerging innovations and treatment options / / Shalini Shah, editor
| Migraine : emerging innovations and treatment options / / Shalini Shah, editor |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (XIV, 240 p. 28 illus., 26 illus. in color.) |
| Disciplina | 616.84912 |
| Soggetto topico |
Migraine - Diagnosis
Migraine - Treatment Migranya Diagnòstic Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-75239-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Migraine Diagnosis and Symptomatology -- 2. Pathophysiology of Migraine Disorder -- 3. Acute Migraine Interventions and Evidence -- 4. Prophylaxis of Migraine Protocols and Options -- 5. CGRP and Immune Modulation Evidence-Based Therapy -- 6. Onabotulinumtoxin A (Botox®) Evidence-Based Therapy -- 7. Pediatric Migraine Presentation and Treatment Algorithm -- 8. Peripheral Nerve Block for the Management of Headache and Face Pain -- 9. Neuromodulation for Migraine Disorders -- 10. Surgical Treatment of Chronic Migraine Headaches -- 11. Dietary Modification and Migraine Relief -- 12. Quick Reference Guides of Commonly Prescribed Drugs and Doses. |
| Record Nr. | UNINA-9910495222703321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Migraine in Medicine : A Machine-Generated Overview of Current Research / / edited by Paolo Martelletti
| Migraine in Medicine : A Machine-Generated Overview of Current Research / / edited by Paolo Martelletti |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (1022 pages) |
| Disciplina | 616.84912 |
| Soggetto topico |
Internal medicine
Public health Internal Medicine Public Health Migranya Diagnòstic diferencial Comorbiditat |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030973599
9783030973582 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Public Health: Epidemiology -- Personal and Societal Impact -- Economics of Migraine -- Governance of Headache Centers. Mechanisms: Genetics -- Biology -- Comorbidities.Lifestyle -- Hormones -- Drug-Drug Interactions. Diagnosis: Classification -- Medical History -- Medication Overuse -- Differential Diagnosis -- Diagnostic Tools: Treatment: Guidelines -- Acute -- Preventive -- Non-pharmacological -- Invasive and non-invasive neuromodulation -- Emergency Management -- Pregnancy -- Childhood and Adolescent -- Elderly -- Outcome Measures and Algorithms -- Infrequent Migraine subtypes. Future Research Directions: Brain Traumas Brain Traumas -- Post-CoVID Epidemiology -- New drugs. |
| Record Nr. | UNINA-9910586579103321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel Synthetic Drugs in Migraine / / edited by Paolo Martelletti, Lars Edvinsson
| Novel Synthetic Drugs in Migraine / / edited by Paolo Martelletti, Lars Edvinsson |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (114 pages) |
| Disciplina |
615.1
616.84912061 |
| Collana | Headache |
| Soggetto topico |
Internal medicine
Neurology Emergency medicine Pain medicine Pharmacology Internal Medicine Emergency Medicine Pain Medicine Migranya |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-95334-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Contents -- Chapter 1: Novel Pharmacological Targets of Migraine: An Overview -- 1.1 Introduction -- 1.2 Novel Pharmacological Treatments for Migraine -- 1.3 Acute Treatment for Migraine Beyond Ergots and Triptans -- 1.3.1 5-HT1F Agonists: Ditans -- 1.3.2 CGRP Receptor Antagonists: Gepants -- 1.4 Gepants as Prophylactic Treatment for Migraine -- 1.5 Mechanisms of Action of Ditans and Gepants: Is It a Common Pathway? -- 1.6 Conclusion -- References -- Chapter 2: Molecular and Cellular Mechanisms of CGRP Antagonists -- 2.1 Introduction -- 2.1.1 Trigeminovascular System -- 2.2 Neuropeptide Signaling -- 2.2.1 CGRP -- 2.2.2 Amylin -- 2.2.3 Neuropeptide Receptors -- 2.2.4 Downstream Activation -- 2.3 The Blood-Brain Barrier -- 2.4 CGRP Antagonists -- 2.5 Molecular Targets -- 2.6 Cellular Targets -- 2.6.1 Vascular Targets -- 2.6.2 Trigeminal Targets -- 2.6.2.1 Satellite Glial Cells -- 2.6.2.2 Neuronal Targets -- 2.6.2.3 Potential Antagonistic Effect at the Nodes of Ranvier -- 2.7 Non-migraine Targets -- 2.8 Conclusion -- References -- Chapter 3: Atogepant -- 3.1 Introduction -- 3.2 Chemical Characteristics, Pharmacodynamics and Pharmacokinetics -- 3.3 Atogepant in Preclinical Studies -- 3.4 Efficacy of Atogepant in Phase II and Phase III Clinical Trials -- 3.5 Safety and Adverse Events -- 3.6 Future Developments -- 3.7 Conclusions -- References -- Chapter 4: Ubrogepant -- 4.1 Introduction -- 4.2 Pharmacology -- 4.2.1 Chemistry -- 4.2.2 Pharmacodynamics -- 4.2.3 Pharmacokinetics and Metabolism -- 4.3 Clinical Registered Trials -- 4.3.1 Phase I Trials -- 4.3.2 Phase II Trials -- 4.3.3 Phase III Trials: ACHIEVE I and II and Their Extension Study -- 4.3.4 Post-marketing Studies -- 4.4 Safety and Tolerability -- 4.5 Regulatory Affairs and Clinical Approval -- 4.6 Conclusions -- References -- Chapter 5: Rimegepant.
5.1 Introduction -- 5.2 Introduction to the Compound -- 5.2.1 Chemistry -- 5.2.2 Pharmacodynamics -- 5.2.3 Pharmacokinetics and Metabolism -- 5.2.4 Metabolism -- 5.2.5 Drug Interactions -- 5.3 Clinical Efficacy -- 5.3.1 Phase II Studies -- 5.3.2 Phase III Studies -- 5.4 Safety and Tolerability -- 5.4.1 Phase I Studies -- 5.4.2 Phase II Studies -- 5.4.3 Phase III Studies -- 5.5 Exclusion Criteria -- 5.6 Conclusions -- References -- Chapter 6: Zavegepant -- 6.1 Introduction -- 6.2 Preclinical Pharmacology -- 6.3 Clinical Trials -- 6.3.1 Safety and Tolerability -- 6.3.2 Efficacy -- 6.4 Conclusion -- References -- Chapter 7: Molecular Mechanisms of 5-HT1F Receptor Agonists -- 7.1 Serotonin (5-HT) and 5-HT Receptors -- 7.2 5-HT1B/D and 5-HT1F Receptors and Migraine Treatment -- References -- Chapter 8: Lasmiditan -- 8.1 Introduction -- 8.2 Pharmacological Profile -- 8.3 Preclinical Studies -- 8.4 Clinical Studies -- 8.5 Safety -- 8.6 Drug Interactions -- 8.7 Conclusion -- References -- Chapter 9: Update on Old and Current Targets for Antimigraine Therapies -- 9.1 Introduction -- 9.2 Current Drugs for Acute Migraine -- 9.2.1 NSAIDs and Other Analgesics -- 9.2.2 5-Hydroxytryptamine Receptors in Migraine -- 9.2.3 Neurokinin Receptors and Blockers -- 9.2.4 Gepants -- 9.3 Targets for Prophylaxis of Migraine -- 9.3.1 Beta-Adrenoceptor Blockers -- 9.3.2 Angiotensin II AT1 Receptor Antagonists -- 9.3.3 Anticonvulsant Drugs -- 9.3.4 Tricyclic Antidepressant -- 9.3.5 Calcium Channel Antagonists -- 9.3.6 Onabotulinum Toxin A -- 9.4 Conclusion -- References. |
| Record Nr. | UNINA-9910568262803321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Migranya
(3)
- Internal Medicine (2)
- Internal medicine (2)
- Comorbiditat (1)
- Diagnòstic (1)